This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Flavimun

Johnson & Johnson

Drug Names(s): Yellow Fever vaccine (CRXL)

Description: Crucell is developing Flavimun, a live, attenuated yellow fever (YF) vaccine of the 17D strain, based on the know how of the well-established vaccine formerly produced by the Robert Koch institute in Germany.

Deal Structure: Flavimun was originally developed by Berna Biotech.

In February 2006, Crucell acquired Berna.

In October 2010, Johnson & Johnson and Crucell announced an agreement whereby Johnson & Johnson, through an affiliate, would acquire all outstanding equity of Crucell that it does not already own for approximately Euro 1.75 billion in a recommended cash tender offer. The acquisition was declared unconditional and completed in February 2011.


Flavimun News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug